The United Kingdom’s ambitious plans to foster growth within its vital life sciences sector are facing significant headwinds, with industry…
Read More
Paris is emerging as a focal point for Europe’s next phase in oncology, as science, capital, and industry converge at Campus Grand Parc.
The recent inauguration of THE HIVE at Campus Grand Parc in Paris marks a significant inflection point for Europe’s oncology…
Read More
Ipsen Acquires Rare Disease Specialist Memo Therapeutics for up to €700 Million, Bolstering Pipeline with Promising BK Polyomavirus Asset
Paris, France – In a significant strategic move to expand its rare disease portfolio, global biopharmaceutical company Ipsen announced today…
Read More
Bocunebart’s PACAP-Targeting Mechanism Positions it as a Potential First-in-Class Therapy in a Thin Pipeline of Novel Late-Stage Candidates
New Data Unveiled for Bocunebart, a Promising Migraine Preventive Targeting a Novel Pathway Munich, Germany – June 29, 2026 –…
Read More
Sanofi’s Nexviazyme Demonstrates Promising Results in Infants with Infantile-Onset Pompe Disease, Paving Way for Potential Label Expansion
Sanofi’s groundbreaking treatment for Pompe disease, Nexviazyme (avalglucosidase alfa), has achieved a significant milestone with the successful completion of the…
Read More
Anixa Biosciences Secures Key Patent for Breast Cancer Vaccine Technology in South Korea, Expanding Global Intellectual Property Portfolio
Anixa Biosciences has achieved a significant milestone in its quest to develop a preventive vaccine for breast cancer, securing a…
Read More
Seven Pharma Companies Selected for FDA PreCheck Pilot Program to Bolster U.S. Drug Supply Chain
The U.S. Food and Drug Administration (FDA) has announced the initial cohort of seven pharmaceutical companies selected to participate in…
Read More
Talawar Therapeutics and JATT II Acquisition Complete Business Combination to Advance Novel Immunology Therapeutics
In a significant development poised to reshape the landscape of immunology therapeutics, New Jersey-based Talawar Therapeutics has officially merged with…
Read More
Sobi Receives Complete Response Letter from FDA for Investigational Gout Therapy NASP, Focus on Manufacturing Deficiencies
Swedish Orphan Biovitrum (Sobi) has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) concerning…
Read More
Biogen Pauses or Terminates Investment in Most of Apellis’ Legacy Research Programs Following $5.6 Billion Acquisition
Three months after Biogen finalized its substantial $5.6 billion acquisition of Apellis Pharmaceuticals, a significant shift in research and development…
Read MoreYOU MAY HAVE MISSED
